| Description |
BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect[1].
|
| Related Catalog |
|
| Target |
IC50: 16 nM (GSK-3α), 21 nM (GSK-3β)[1]
|
| In Vitro |
BIP-135 (20-30 μM; 72 hours) increases the survival motor neuron (SMN) protein levels at a dose of 25 μM in human SMA fibroblasts. And the typical bell-shaped dose-response curve is observed due to some toxicity at higher concentrations[1]. BIP-135 (20 μM; 48 hours) is a superior neuroprotective agent in the model of oxidative stress[1]. Western Blot Analysis[1] Cell Line: Human SMA fibroblasts Concentration: 20 μM, 25 μM, 30 μM Incubation Time: 72 hours Result: Led to a 7-fold increase in SMN levels at 25 μM.
|
| In Vivo |
BIP-135 does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight)[1]. BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy[1]. Animal Model: Male and female SMN2+/+, SMN2Δ7+/+, Smn+/– mice[1] Dosage: 75 mg/kg Administration: Intraperitoneal injection; daily; from postnatal day 0 to 21 Result: Caused a modest extension in the median survival of SMA KO animals by two days.
|
| References |
[1]. Chen PC, et al. Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci. 2012 Jan 18;3(1):5-11.
|
